a Department of Pharmaceutics, Faculty of Pharmacy , Ahram Canadian University , Cairo , Egypt.
b Department of Pharmaceutics, Faculty of Pharmacy , Cairo University , Cairo , Egypt , and.
Drug Deliv. 2016 Oct;23(8):2736-2746. doi: 10.3109/10717544.2015.1064187. Epub 2015 Jul 13.
Gastro retentive drug delivery system techniques were adopted to deliver drugs having narrow absorption window from a particular site in the GIT. Therefore, gastro retentive dosage forms were retained in the stomach, thus improving absorption and bioavailability would be improved consequently. In this study, cinnarizine (CNZ) was employed as the model drug. CNZ is a poorly soluble basic drug, suffering from low and erratic bioavailability. This is attributed to its pH-dependant solubility (highly soluble at pH < 4). CNZ is characterized by short half-life (3-6 h). Accordingly, floating CNZ emulsion gel calcium pectinate beads were developed. A mixture design was employed to study the effect of the percent of LM pectin (A), the percent of GMO (B) and the percent of Labrafac Lipophile (C) simultaneously on the percent of drug released and loaded. The optimized floating CNZ emulsion gel calcium pectinate beads and Stugeron® (the marketed reference product) were compared through a pharmacokinetic study carried on healthy human volunteers. Fortunately, simple floating CNZ emulsion gel calcium pectinate beads were prepared with zero-order release profile for 12 h. A promising in-vivo CNZ controlled release dosage form with higher bioavailability, when compared to once daily administration of Stugeron® tablets was achieved.
采用胃滞留药物传递系统技术将具有狭窄吸收窗的药物从胃肠道的特定部位递送到体内。因此,胃滞留剂型在胃中被保留,从而提高了吸收,生物利用度也随之提高。在本研究中,肉桂嗪(CNZ)被用作模型药物。CNZ 是一种难溶性的碱性药物,其生物利用度低且不稳定。这归因于其 pH 依赖性溶解度(在 pH < 4 时高度溶解)。CNZ 的半衰期较短(3-6 h)。因此,开发了漂浮的 CNZ 乳凝胶藻酸钠珠。采用混合设计同时研究了 LM 果胶(A)的百分比、GMO(B)的百分比和 Labrafac Lipophile(C)的百分比对药物释放百分比和载药量的影响。通过对健康人体志愿者进行的药代动力学研究,比较了优化的漂浮 CNZ 乳凝胶藻酸钠珠和 Stugeron®(市售参考产品)。幸运的是,简单的漂浮 CNZ 乳凝胶藻酸钠珠以零级释放模式持续 12 小时。与每日一次服用 Stugeron®片剂相比,实现了具有更高生物利用度的有前途的体内 CNZ 控释剂型。